Sagimet Biosciences Inc.

SGMT

Sagimet Biosciences Inc.

SGMT

Insider Sentiment (TTM):

Last Purchase:2024-03-26Last Sale:2026-02-10Shares Purchased (TTM):0Shares Sold (TTM):57,363

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:13,130,229Shares Outstanding:32,559,704Institutional Ownership Pct.:40.33%

Earnings Market Reaction:

Filing Date:2026-08-11Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Series Common Stock Warrants	-	-	-	-	-	-	-	-	-	-	-	0
Common Class A	-	0	0	0	0	31	31	0	0	30	21	21
Common Class B	-	1	1	0	0	2	2	0	0	2	2	2
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	166	37	35	32	42	65	76	77	96	177	75	102
Marketable Securities Current	74	68	78	84	83	80	75	75	70	17	20	0
Prepaid Expense And Other Assets Current	4	3	3	3	2	2	2	5	0	1	2	1
Assets Current	244	108	116	119	127	146	153	157	167	194	97	103
Marketable Securities Noncurrent	-	-	0	9	10	-	7	17	22	-	-	-
Operating Lease Right Of Use Asset	2	0	0	0	0	0	0	0	0	0	0	0
Assets	263	108	116	128	137	146	160	175	189	195	97	103
Liabilities And Stockhold…
Liabilities Current
Other Assets Noncurrent	-	-	-	-	-	0	-	-	-	-	-	-
Accounts Payable Current	1	2	1	4	2	3	1	1	2	1	0	2
Accrued Liabilities Current	4	3	4	5	5	4	3	3	4	4	5	3
Operating Lease Liability Current	0	0	0	0	0	0	0	0	0	0	0	0
Liabilities	-	-	-	-	-	7	-	4	6	5	6	5
Liabilities Current	5	5	5	9	7	-	4	-	-	-	6	5
Liabilities Noncurrent
Stockholders Equity Inclu…
Preferred Stock Value	0	0	0	0	0	-	0	-	-	-	-	-
Additional Paid In Capital	627	459	458	456	454	452	451	449	448	446	341	339
Retained Earnings Accumulated Deficit	-371	-357	-346	-337	-324	-313	-295	-279	-264	-256	-250	-242
Accumulated Other Comprehensive Income Loss Net Of…	-0	0	0	0	0	0	0	0	-0	0	0	-
Stockholders Equity	256	102	111	119	130	139	156	171	183	190	91	98
Liabilities And Stockholders Equity	263	108	116	128	137	146	160	175	189	195	97	103
Related Party	-	-	-	-	-	-	0	-0	-0	0	0	-
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Temporary Equity Par Or Stated Value Per Share	-	-	-	-	-	-	-	-	-	-	0	-
Temporary Equity Shares Authorized	-	-	-	-	-	-	-	-	-	-	0	0
Temporary Equity Shares Issued	-	-	-	-	-	-	-	-	-	-	0	0
Temporary Equity Shares Outstanding	-	-	-	-	-	-	-	-	-	-	0	0
Common Stock Par Or Stated Value Per Share	-	-	-	-	-	-	-	-	0	0	0	-
Common Stock Shares Authorized	-	-	-	-	-	-	-	-	-	-	0	0
Common Stock Shares Issued	-	-	-	-	-	-	-	-	-	-	0	0
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	0	0

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-11.63%	-0.52%	-4.44%	-	-	-	-	-	-	-	-	-
2025	10.94%	145.94%	220.00%	-25.78%	-23.90%	-11.06%	-17.44%	-22.61%	-26.74%	-7.32%	32.58%	27.00%
2024	1.73%	-35.93%	-33.55%	2.02%	65.59%	115.79%	-1.54%	-4.05%	-15.06%	-40.74%	9.12%	1.14%
2023	-	-	-	-3.17%	-55.00%	-79.00%	62.78%	114.80%	350.67%	-23.18%	-11.49%	-20.69%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	45.02	20.34	22.82	13.06	17.55	-	34.30	-	-	-	17.09	20.36
Quick Ratio	44.31	19.74	22.18	12.76	17.30	-	33.96	-	-	-	16.78	20.17
Working Capital	238.57M	102.42M	111.30M	110.33M	119.95M	-	148.32M	-	-	-	90.99M	97.77M
Leverage & Debt
Debt to Equity	0.02	0.05	0.05	0.08	0.06	-	0.03	-	-	-	0.06	0.05
Debt Ratio	0.02	0.05	0.04	0.07	0.05	-	0.03	-	-	-	0.06	0.05
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.04	0.02	-	-
Per Share Metrics
Diluted EPS TTM	-0.89	-1.34	-1.58	-1.78	-1.84	-1.77	-1.45	-1.37	-1.12	-1.19	-	-
Free Cash Flow Per Share TTM	-0.90	-1.22	-1.41	-0.93	-1.23	-1.58	-1.35	-1.20	-0.71	-1.03	-	-
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-
Margin Metrics
Operating Profit Margin TTM	-	-	-	-	-	-	-	-2,624.50%	-1,076.00%	-987.70%	-	-
Net Profit Margin TTM	-	-	-	-	-	-	-	-2,205.20%	-895.95%	-862.63%	-	-
Growth Metrics
Net Revenue Growth (1Y)	-	-	-	-100.00%	-100.00%	-100.00%	-	-	-	-	-	-
Net Income Growth (1Y)	-20.72%	-23.82%	12.01%	30.76%	65.70%	65.52%	-	-	-	-	-	-
EPS Growth (1Y)	-51.94%	-24.67%	8.56%	29.47%	64.25%	49.30%	-	-	-	-	-	-
Valuation Metrics
P/E TTM	-8.72	-3.91	-3.75	-3.86	-4.13	-1.84	-3.10	-2.02	-3.05	-4.56	-	-
P/B TTM	1.60	1.66	1.72	1.87	1.88	0.76	0.91	0.52	0.60	0.83	0.62	1.64
P/S TTM	-	-	-	-	-	-	-	44.52	27.29	39.35	-	-
Market Cap	410.58M	170.12M	191.49M	222.71M	245.33M	104.96M	141.08M	89.04M	109.15M	157.39M	56.70M	160.11M
Enterprise Value	244.68M	133.50M	156.46M	190.21M	203.00M	40.24M	65.24M	12.02M	13.19M	-19.38M	-18.44M	58.27M
Calculated Values
Free Cash Flow TTM	-47.65M	-39.73M	-45.65M	-30.31M	-39.69M	-50.76M	-42.44M	-38.49M	-22.80M	-29.97M	-	-
Net Debt	-165.90M	-36.63M	-35.02M	-32.50M	-42.33M	-64.72M	-75.84M	-77.01M	-95.96M	-176.78M	-75.14M	-101.84M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-02-10Sale

Owner: Rozek, Elizabeth

Title: Chief Legal & Admin. Officer

Shares: 2,622

Price/Share: $5.36

Value: $14,053.92

Shares Owned: 190,959

Relationship: Officer

Ownership: Direct

2026-02-10Sale

Owner: Chauche, Thierry

Title: Chief Financial Officer

Shares: 1,312

Price/Share: $5.36

Value: $7,032.32

Shares Owned: 15,688

Relationship: Officer

Ownership: Direct

2026-02-10Sale

Owner: Martins, Eduardo Bruno

Title: Chief Medical Officer

Shares: 3,640

Price/Share: $5.36

Value: $19,510.40

Shares Owned: 103,296

Relationship: Officer

Ownership: Direct

2026-02-10Sale

Owner: Happel, David

Title: President & CEO

Shares: 12,101

Price/Share: $5.36

Value: $64,861.36

Shares Owned: 677,621

Relationship: Director,Officer

Ownership: Direct

2025-11-20Sale

Owner: Kemble, George

Title: Executive Chairman

Shares: 37,688

Price/Share: $7.69

Value: $289,820.72

Shares Owned: 81,005

Relationship: Director,Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-02-10	Rozek, Elizabeth	Officer	Chief Legal & Admin. Officer	Direct	Sale	2,622	5.36	$14,053.92	190,959	4
2026-02-10	Chauche, Thierry	Officer	Chief Financial Officer	Direct	Sale	1,312	5.36	$7,032.32	15,688	4
2026-02-10	Martins, Eduardo Bruno	Officer	Chief Medical Officer	Direct	Sale	3,640	5.36	$19,510.40	103,296	4
2026-02-10	Happel, David	Director,Officer	President & CEO	Direct	Sale	12,101	5.36	$64,861.36	677,621	4
2025-11-20	Kemble, George	Director,Officer	Executive Chairman	Direct	Sale	37,688	7.69	$289,820.72	81,005	4
2025-07-21	Happel, David	Director,Officer	President & CEO	Direct	Sale	65,478	9.13	$597,814.14	689,722	4
2025-07-21	Martins, Eduardo Bruno	Officer	Chief Medical Officer	Direct	Sale	8,277	9.13	$75,569.01	106,936	4
2025-07-21	Rozek, Elizabeth	Officer	General Counsel and CCO	Direct	Sale	10,780	9.13	$98,421.40	183,726	4
2024-07-23	Kemble, George	Director,Officer	Executive Chairman	Direct	Sale	23,625	3.17	$74,891.25	118,693	4
2024-07-19	Martins, Eduardo Bruno	Officer	Chief Medical Officer	Direct	Sale	8,357	3.10	$25,906.70	81,213	4
2024-07-19	Kemble, George	Director,Officer	Executive Chairman	Direct	Sale	14,062	3.10	$43,592.20	142,318	4
2024-07-19	Rozek, Elizabeth	Officer	General Counsel and CCO	Direct	Sale	10,914	3.10	$33,833.40	160,506	4
2024-03-26	Happel, David	Director,Officer	President & CEO	Direct	Purchase	12,100	5.27	$63,767.00	639,200	4
2023-12-07	Happel, David	Director,Officer	President & CEO	Direct	Purchase	1,600	4.10	$6,560.00	627,100	4
2023-11-16	Happel, David	Director,Officer	President & CEO	Direct	Purchase	590	2.35	$1,386.50	590	4
2023-07-18	Seidenberg, Beth C	Director	-	Indirect	Purchase	46,875	16.00	$750,000.00	46,875	4
2023-07-18	Kerins, Patrick J, Nea Pa…	TenPercentOwner	-	Direct	Purchase	30,000	16.00	$480,000.00	3,850,275	4
2023-07-18	Kerins, Patrick J, Nea Pa…	TenPercentOwner	-	Direct	Sale	662	16.00	$10,592.00	3,820,275	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

40.33%

Inst. Shares: 13,130,229

Shares Outstanding: 32,559,704

2025-12-31

43.87%

Inst. Shares: 14,188,930

Shares Outstanding: 32,345,525

2025-09-30

38.26%

Inst. Shares: 12,419,551

Shares Outstanding: 32,464,893

2025-06-30

35.52%

Inst. Shares: 11,434,833

Shares Outstanding: 32,195,366

2025-03-31

41.93%

Inst. Shares: 13,498,080

Shares Outstanding: 32,195,345

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	13,130,229	32,559,704	40.33%
2025-12-31	14,188,930	32,345,525	43.87%
2025-09-30	12,419,551	32,464,893	38.26%
2025-06-30	11,434,833	32,195,366	35.52%
2025-03-31	13,498,080	32,195,345	41.93%
2024-12-31	17,190,403	31,350,725	54.83%
2024-09-30	19,160,980	32,143,336	59.61%
2024-06-30	20,368,451	31,913,887	63.82%
2024-03-31	21,978,282	29,039,427	75.68%
2023-12-31	13,465,474	10,460,335	128.73%
2023-09-30	14,610,961	18,194,682	80.30%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Sagimet Biosciences Inc. (SGMT) — SEC Financial Statements & Analysis

Sagimet Biosciences Inc. (SGMT) is a pharmaceutical preparations company, incorporated in DE. Sagimet Biosciences Inc. trades on Nasdaq as: SGMT. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Sagimet Biosciences Inc. reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of 0.02x, a Price-to-Sales (P/S) ratio of 44.52x (TTM), a Price-to-Book (P/B) ratio of 1.60x (TTM), at a market cap of $410.58M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Debt To Equity: 0.02x
P/S TTM: 44.52x
P/B TTM: 1.60x
Market Cap: $410.58M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Sagimet Biosciences Inc. in?

Sagimet Biosciences Inc. (SGMT) operates in the Pharmaceutical Preparations industry.

What is SGMT's market cap?

Sagimet Biosciences Inc. (SGMT) has a market capitalization of $410.58M as of 2026-06-30.

What exchange does SGMT trade on?

Sagimet Biosciences Inc. (SGMT) trades on the Nasdaq.

Where is Sagimet Biosciences Inc. incorporated?

Sagimet Biosciences Inc. is incorporated in DE.